RxDoctor Payments Data

Andreea Seicean

Psychiatry · Rockville, MDNPI 1518354414

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,960 of the $14,538 with a category attached, or 61.6%. Johnson & Johnson accounts for 71.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $6,902 and has fallen 81.0% since, to $1,311 in 2025. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,538in general payments, 2019–2025

Across 221 payments — averaging $65.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$10K
  • AbbVie$806
  • Lundbeck LLC$702
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$420
  • Corium, LLC$353
  • Otsuka America Pharmaceutical, Inc.$309
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$8,96062%
  • Travel & lodging$7735%
  • Food & beverage$4,78533%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,538 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$33,517
VraylarCariprazine Hcl20$28,881
TrintellixVortioxetine Hydrobromide11$10,463
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl69$5,247
Lisdexamfetamine Dimesylate19$3,488
Gabapentin47$1,835
Lamotrigine59$1,433
Quetiapine Fumarate50$743
Modafinil30$719
Buspirone Hcl26$712
Clonazepam62$626
Fluoxetine Hcl60$537
Methylphenidate Hcl22$414
Topiramate30$354
Mirtazapine20$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$309$33,51720 claims
AbbVieVraylar$806$28,88120 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$171$10,46311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →